0
0
New Delhi, July 22, 2025
The Indian Council of Medical Research (ICMR) has officially invited eligible organizations, companies, and manufacturers to submit Expressions of Interest (EoIs) for the technology transfer and commercialization of its validated Chikungunya IgM ELISA Kit. Developed by the ICMR-National Institute of Virology, this diagnostic kit is designed for the detection of IgM antibodies against the Chikungunya virus, which is pivotal for the timely diagnosis and management of the disease.
Key Details of the Initiative
-
Objective: The technology transfer aims to enable the commercial production and wider distribution of the Chikungunya IgM ELISA Kit to address public health needs and support clinical diagnosis in suspected cases.
-
Scope: The selected company or companies will receive rights for further development, manufacturing, and commercialization of the kit on either an exclusive or non-exclusive basis.
-
Technology Readiness: The ELISA kit technology is fully standardized, is currently in regular production, and has already been supplied to surveillance hospitals and referral laboratories under national programs.
-
Performance: The kit has undergone extensive validation, demonstrating a diagnostic sensitivity of 95% and specificity of 98%, ensuring high reliability and accuracy in detecting recent Chikungunya infections.
-
Support: ICMR-NIV will provide technical guidance and oversight at all stages, facilitating rapid product development and market introduction.
Significance for Public Health
Chikungunya, transmitted by Aedes aegypti mosquitoes, remains a significant health challenge in tropical regions. Accurate and prompt diagnosis with tools such as the ELISA kit can help in controlling outbreaks and guiding effective patient care. The technology’s cost-effectiveness and robust performance make it a suitable choice for mass deployment within India’s healthcare system.
Application Process
Interested organizations are required to register and submit their EoIs via the Medical Innovation Patent Mitra portal. Detailed eligibility criteria and submission guidelines are available through the ICMR website. The last date for EoI submission is July 27, 2025.
Disclaimer
This article summarizes publicly available information regarding the ICMR’s invitation for EoIs for the technology transfer of the Chikungunya IgM Antibody Detection Kit. Readers are advised to consult the official ICMR documentation and announcements for the most accurate and updated details regarding eligibility, application procedures, and technical specifications. This content does not constitute official policy or legal advice.
